The new blueprint for biotech: RNA editing and radioligand therapy

Breakthroughs in RNA editing and radioligand therapies are poised to take biotech into a new era – driving innovation, growth and new investment opportunities Biotechnology is entering a dynamic new ...

While there are bubbles in the stock market, this sector looks dirt cheap

There’s a lot of froth in the stock market right now. Yet at the same time, there are also a lot of bargains for long-term investors. The post While there are bubbles in the stock market, this sector ...

PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with ...